Cargando…

Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection

Venezuelan equine encephalitis virus (VEEV) is a category B select agent pathogen that can be aerosolized. Infections in murine models and humans can advance to an encephalitic phenotype which may result in long-term neurological complications or death. No specific FDA-approved treatments or vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Risner, Kenneth, Ahmed, Aslaa, Bakovic, Allison, Kortchak, Stephanie, Bhalla, Nishank, Narayanan, Aarthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950191/
https://www.ncbi.nlm.nih.gov/pubmed/31842327
http://dx.doi.org/10.3390/v11121151
_version_ 1783486013870440448
author Risner, Kenneth
Ahmed, Aslaa
Bakovic, Allison
Kortchak, Stephanie
Bhalla, Nishank
Narayanan, Aarthi
author_facet Risner, Kenneth
Ahmed, Aslaa
Bakovic, Allison
Kortchak, Stephanie
Bhalla, Nishank
Narayanan, Aarthi
author_sort Risner, Kenneth
collection PubMed
description Venezuelan equine encephalitis virus (VEEV) is a category B select agent pathogen that can be aerosolized. Infections in murine models and humans can advance to an encephalitic phenotype which may result in long-term neurological complications or death. No specific FDA-approved treatments or vaccines are available for the treatment or prevention of VEEV infection. Neurotropic viral infections have two damaging components: neuronal death caused by viral replication, and damage from the subsequent inflammatory response. Reducing the level of inflammation may lessen neurological tissue damage that often arises following VEEV infection. In this study, three commercially available anti-inflammatory drugs, Celecoxib, Rolipram, and Tofacitinib, were evaluated for antiviral activity in an astrocyte and a microglial model of VEEV infection. The inhibitors were tested against the vaccine strain VEEV TC-83, as well as the wild-type VEEV Trinidad donkey strain. Celecoxib, Tofacitinib, and Rolipram significantly decreased viral titers both after pre-treatment and post-treatment of infected cells. VEEV Trinidad Donkey (TrD) titers were reduced 6.45-fold in cells treated with 50 µM of Celecoxib, 2.45-fold when treated with 50 µM of Tofacitinib, and 1.81-fold when treated with 50 µM of Rolipram. Celecoxib was also shown to decrease inflammatory gene expression in the context of TC-83 infection. Overall, Celecoxib demonstrated potency as a countermeasure strategy that slowed VEEV infection and infection-induced inflammation in an in vitro model.
format Online
Article
Text
id pubmed-6950191
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69501912020-01-16 Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection Risner, Kenneth Ahmed, Aslaa Bakovic, Allison Kortchak, Stephanie Bhalla, Nishank Narayanan, Aarthi Viruses Article Venezuelan equine encephalitis virus (VEEV) is a category B select agent pathogen that can be aerosolized. Infections in murine models and humans can advance to an encephalitic phenotype which may result in long-term neurological complications or death. No specific FDA-approved treatments or vaccines are available for the treatment or prevention of VEEV infection. Neurotropic viral infections have two damaging components: neuronal death caused by viral replication, and damage from the subsequent inflammatory response. Reducing the level of inflammation may lessen neurological tissue damage that often arises following VEEV infection. In this study, three commercially available anti-inflammatory drugs, Celecoxib, Rolipram, and Tofacitinib, were evaluated for antiviral activity in an astrocyte and a microglial model of VEEV infection. The inhibitors were tested against the vaccine strain VEEV TC-83, as well as the wild-type VEEV Trinidad donkey strain. Celecoxib, Tofacitinib, and Rolipram significantly decreased viral titers both after pre-treatment and post-treatment of infected cells. VEEV Trinidad Donkey (TrD) titers were reduced 6.45-fold in cells treated with 50 µM of Celecoxib, 2.45-fold when treated with 50 µM of Tofacitinib, and 1.81-fold when treated with 50 µM of Rolipram. Celecoxib was also shown to decrease inflammatory gene expression in the context of TC-83 infection. Overall, Celecoxib demonstrated potency as a countermeasure strategy that slowed VEEV infection and infection-induced inflammation in an in vitro model. MDPI 2019-12-12 /pmc/articles/PMC6950191/ /pubmed/31842327 http://dx.doi.org/10.3390/v11121151 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Risner, Kenneth
Ahmed, Aslaa
Bakovic, Allison
Kortchak, Stephanie
Bhalla, Nishank
Narayanan, Aarthi
Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title_full Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title_fullStr Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title_full_unstemmed Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title_short Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
title_sort efficacy of fda-approved anti-inflammatory drugs against venezuelan equine encephalitis virus infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950191/
https://www.ncbi.nlm.nih.gov/pubmed/31842327
http://dx.doi.org/10.3390/v11121151
work_keys_str_mv AT risnerkenneth efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection
AT ahmedaslaa efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection
AT bakovicallison efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection
AT kortchakstephanie efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection
AT bhallanishank efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection
AT narayananaarthi efficacyoffdaapprovedantiinflammatorydrugsagainstvenezuelanequineencephalitisvirusinfection